Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
Laure A Moutouh-de Parseval(Novartis (Switzerland)), Kyle Chan, Gregory D. Ferguson(Ferring Pharmaceuticals (United Kingdom)), Kristen Jensen-Pergakes, Dominique Verhelle(Pfizer (United States)), Christopher Morris(University of South Florida), Laura G. Corral, Helen Brady, George W. Muller(University of Leeds), Emilia Glezer
Cited by 180
Related Papers
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586